Objective:To identify the relationship between interleukin(IL)-15 levels and sarcopenia in human immunodeficiency virus(HIV)-infected patients who have received antiretroviral therapy.Methods:This study was a cross-se...Objective:To identify the relationship between interleukin(IL)-15 levels and sarcopenia in human immunodeficiency virus(HIV)-infected patients who have received antiretroviral therapy.Methods:This study was a cross-sectional design with 70 participants conducted from January to March 2021.All the participants were assessed for sarcopenia and the IL-15 levels.Sarcopenia was established based on the the Asian Working Group for Sarcopenia(AWGS)2019 criteria.Plasma IL-15 was determined.This analysis was carried out by means of 2×2 tabulation and the statistical test used is Chi-square.Results:Seventy patients received antiretroviral therapy>6 months and showed a good clinical response.Among them,36(51.4%)took zidovudine-based antiretroviral therapy with a median duration of illness of 5 years.The proportion of sarcopenia in patients with HIV infection was 32.9%.The median CD4 cell count was 395.5 cells/L(range:203-937 cells/L).Logistic regression analysis revealed that age>50 years(aOR 8.3,95%CI 1.6-44.5),underweight(aOR 7.7,95%CI 1.5-40.5),IL-15≥150.5 ng/L(aOR 4.9,95%CI 1.3-19.0)and female(aOR 4.8,95%CI 1.2-18.3 were significant and independent adverse predictors of sarcopenia in subjects with HIV infection.Conclusions:There is an association between high levels of IL-15 and sarcopenia in HIV-infected patients on antiretroviral therapy for more than 6 months with good clinical response.展开更多
文摘Objective:To identify the relationship between interleukin(IL)-15 levels and sarcopenia in human immunodeficiency virus(HIV)-infected patients who have received antiretroviral therapy.Methods:This study was a cross-sectional design with 70 participants conducted from January to March 2021.All the participants were assessed for sarcopenia and the IL-15 levels.Sarcopenia was established based on the the Asian Working Group for Sarcopenia(AWGS)2019 criteria.Plasma IL-15 was determined.This analysis was carried out by means of 2×2 tabulation and the statistical test used is Chi-square.Results:Seventy patients received antiretroviral therapy>6 months and showed a good clinical response.Among them,36(51.4%)took zidovudine-based antiretroviral therapy with a median duration of illness of 5 years.The proportion of sarcopenia in patients with HIV infection was 32.9%.The median CD4 cell count was 395.5 cells/L(range:203-937 cells/L).Logistic regression analysis revealed that age>50 years(aOR 8.3,95%CI 1.6-44.5),underweight(aOR 7.7,95%CI 1.5-40.5),IL-15≥150.5 ng/L(aOR 4.9,95%CI 1.3-19.0)and female(aOR 4.8,95%CI 1.2-18.3 were significant and independent adverse predictors of sarcopenia in subjects with HIV infection.Conclusions:There is an association between high levels of IL-15 and sarcopenia in HIV-infected patients on antiretroviral therapy for more than 6 months with good clinical response.
